Navigation Links
DUSA Pharmaceuticals Named to Deloitte's 2009 Technology Fast 500 List of Fastest Growing Companies in North America
Date:10/21/2009

Second Consecutive Year DUSA Has Been Recognized

WILMINGTON, Mass., Oct. 21 /PRNewswire-FirstCall/ -- DUSA Pharmaceuticals, Inc.(R)( )(Nasdaq: DUSA), a specialty pharmaceutical company focused on dermatology, announced today that it has been named to Deloitte's Technology Fast 500 list. For the second consecutive year, Deloitte recognized DUSA as one of the Top 500 fastest growing technology, media, telecommunications and life sciences companies in North America in terms of percentage revenue growth over a five year period.

"DUSA is pleased to receive this elite recognition from Deloitte for the second year in a row," said Bob Doman, DUSA's President and Chief Executive Officer. "Despite the current economic environment, clinicians continue to embrace Levulan(R) Photodynamic Therapy (PDT) based on its clinical efficacy and patient satisfaction in the treatment of actinic keratoses (AKs)."

Levulan PDT, one of the fastest growing procedures in dermatology, is currently approved for the treatment of Grade 1 and 2 AKs of the face and scalp. AKs are the most frequently diagnosed skin disease by U.S. dermatologists with over 5M treatment visits per year. Through the first six months of 2009, U.S. PDT revenue grew 22%. DUSA is also in clinical development of its Levulan PDT technology platform for the treatment of AKs and the prevention of squamous cell carcinomas in chronically immunosuppressed solid organ transplant recipients.

Technology Fast 500 Selection and Qualifying Criteria

Technology Fast 500 provides a ranking of the fastest growing technology, media, telecommunications, life sciences and clean technology companies in North America. This ranking is compiled from nominations submitted directly to the Technology Fast 500 website, and public company database research conducted by Deloitte LLP. Technology Fast 500 award winners for 2009 are selected based on percentage fiscal year revenue growth during the five year period from 2004 to 2008.

To be considered, Technology Fast 500 entrants must meet the following criteria:

  • Must own proprietary intellectual property or proprietary technology that contributes to a significant portion of the company's operating revenues.
  • Base-year operating revenues must be at least $50,000 USD or CD, and current-year operating revenues must be at least $5 million USD or CD.
  • Be in business a minimum of five years.
  • Be headquartered in North America.

The complete 2009 Deloitte Technology Fast 500 report is available online: http://www.deloitte.com/view/en_US/us/Industries/Technology/technologyfast500/index.htm.

About Actinic Keratoses

Actinic keratoses are rough-textured, dry, scaly patches on the skin caused by excessive exposure to ultraviolet light, such as sunlight. They occur most frequently on sun exposed areas such as the face, scalp, ears, neck, hands and arms. They form on the outermost layer of skin and they can range in color from skin toned to reddish brown. They can also range in size from as small as a pinhead to larger than a quarter.

About DUSA Pharmaceuticals

DUSA Pharmaceuticals, Inc.(R)( )is an integrated dermatology pharmaceutical company focused primarily on the development and marketing of its Levulan(R) Photodynamic Therapy technology platform, and complementary dermatology products. Levulan PDT is currently approved for the treatment of Grade 1 and 2 actinic keratoses of the face and scalp. DUSA also markets other dermatology products, including ClindaReach(R). DUSA is researching Levulan PDT for the treatment of AKs and the reduction of new non-melanoma skin cancer in chronically immunosuppressed solids organ transplant recipients. DUSA is based in Wilmington, Mass. Please visit our Web site at www.dusapharma.com.

About Deloitte

As used in this document, "Deloitte" means Deloitte LLP. Please see www.deloitte.com/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries.

SOURCE DUSA Pharmaceuticals, Inc.


'/>"/>
SOURCE DUSA Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Peregrine Pharmaceuticals Announces Implementation of 1:5 Reverse Stock Split to Take Effect October 19, 2009
2. Proteolix, Inc. to be Acquired By Onyx Pharmaceuticals
3. Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
4. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
5. Onyx Pharmaceuticals to Host Investor Briefing Following ECCO/ESMO Oncology Congress
6. Biostar Pharmaceuticals, Inc. to Present at the Maxim Group Growth Conference on September 29 at 2:00pm ET
7. DUSA Pharmaceuticals to Present at the Maxim Group 3rd Annual Growth Conference
8. With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals, Inc. and RealAge.com Launch Effort to Educate Americans
9. With Economic Pain Contributing to Minor Strains and Sprains, King Pharmaceuticals(R), Inc. and RealAge.com Launch Effort to Educate Americans on Prevention and Treatment
10. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
11. VIA Pharmaceuticals Receives Anticipated Deficiency Notice From NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... U.S. Security Associates (USA) ... 125 for their industry leading training methods that engage their associates and link ... the global elite in employer-sponsored training and development programs. , “The 2017 Training ...
(Date:12/5/2016)... (PRWEB) , ... December 06, 2016 , ... For many ... Lithuanian poetry , both thick and thin. The beauty of the Lithuanian language ... Trafford Publishing). , In this poetry book, Zubinas lyrically explores all aspects of a ...
(Date:12/5/2016)... ... 2016 , ... “Epilepsy Awareness,” which can be found at ... conversation about epilepsy, bearing down on the social stigma and lack of public ... epilepsy within their lifetime. With such a large percentage of people affected, it’s ...
(Date:12/5/2016)... ... ... BSI and Brenntag Canada have been appointed by Chr. Hansen as their ... fruits and beverage colorants effective November 1, 2016. , “The ... product portfolio,” said Steve Brauer, President of Brenntag Specialties, Inc. “Representing Chr. Hansen will ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ("GPP") portfolio company, today announced it has acquired the assets of Frankfurt, ... previously a subsidiary of Chiltern International and focuses on clinical trial drug ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... OSWEGO, Ore. , Dec. 5, 2016   ... the BioInsight clinical study. The study evaluates the safety ... insertion procedure in an office setting. BioMonitor ... ® technology that is placed underneath a patient,s ... fibrillation and syncope (fainting). Atrial fibrillation is a leading ...
(Date:12/5/2016)... --  TrainerMD , the first HIPAA compliant software collaboration platform for ... Styku . Styku, a California -based ... users world-class, real-time 3D body scanning and analysis. Together with its ... hear and feel their health like never before. ... , , ...
(Date:12/5/2016)... 5, 2016  Recently Zymo Research announced an ... known as Horvath,s Clock. Based on this technology, ... service to academic and biopharma scientific researchers to ... other than sperm. The service quantifies ... age versus chronological age following drug treatments and ...
Breaking Medicine Technology: